Elie Fadel

Elie Fadel

Auto-generated profile, based on publicly available information

Elie Fadel

Inserm, Hypertension Pulmonaire: Physiopathologie et Innovation Thérapeutique, Université Paris-Saclay, 92350 Le Plessis Robinson, France

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2018 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
YTYuichi Tamura
Yuichi Tamura
CPCarole Phan
Carole Phan
LTLy TU
Ly TU
MHMorane Le Hiress
Morane Le Hiress
RTRaphaël Thuillet
Raphaël Thuillet
Christophe GuignabertChristophe Guignabert
Christophe Guignabert
Pulmonary arterial hypertension (PAH) is characterized by a progressive accumulation of pulmonary artery smooth muscle cells (PA-SMCs) in pulmonary arterioles leading to the narrowing of the lumen, right heart failure, and death. Although most studies have supported the notion of a role for IL-6/glycoprotein 130 (gp130) signaling in PAH, it remains unclear how this signaling pathway determines the progression of the disease. Here, we identify ectopic upregulation of membrane-bound IL-6 receptor (IL6R) on PA-SMCs in PAH patients and in rodent models of pulmonary hypertension (PH) and demonstrate its key role for PA-SMC accumulation in vitro and in vivo. Using Sm22a-Cre Il6rfl/fl, which lack Il6r in SM22A-expressing cells, we found that these animals are protected against chronic hypoxia–induced PH with reduced PA-SMC accumulation, revealing the potent pro-survival potential of membrane-bound IL6R. Moreover, we determine that treatment with IL6R-specific antagonist reverses experimental PH in two rat models. This therapeutic strategy holds promise for future clinical studies in PAH.

1 August 2014 in Journal of Autoimmunity
Verified
Journal Article
Closed access
AGAngeline Gradolatto
Angeline Gradolatto
DNDani Nazzal
Dani Nazzal
FTFrédérique Truffault
Frédérique Truffault
JBJacky Bismuth
Jacky Bismuth
EFElie Fadel
Elie Fadel
SBSonia Berrih-Aknin
Sonia Berrih-Aknin

15 January 2015 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
MMMarie Maurer
Marie Maurer
SBSylvain Bougoin
Sylvain Bougoin
Tali FefermanTali Feferman
Tali Feferman
MFMélinée Frenkian
Mélinée Frenkian
JBJacky Bismuth
Jacky Bismuth
SBSonia Berrih-Aknin
Sonia Berrih-Aknin
Anti-acetylcholine receptor (AChR) autoantibodies target muscles in spontaneous human myasthenia gravis (MG) and its induced experimental autoimmune model MG (EAMG). The aim of this study was to identify novel functional mechanisms occurring in the muscle pathology of myasthenia. A transcriptome analysis performed on muscle tissue from MG patients (compared with healthy controls) and from EAMG rats (compared with control rats) revealed a deregulation of genes associated with the Interleukin-6 (IL-6) and Insulin-Like Growth Factor 1 (IGF-1) pathways in both humans and rats. The expression of IL-6 and its receptor IL-6R transcripts was found to be altered in muscles of EAMG rats and mice compared with control animals. In muscle biopsies from MG patients, IL-6 protein level was higher than in control muscles. Using cultures of human muscle cells, we evaluated the effects of anti-AChR antibodies on IL-6 production and on the phosphorylation of Protein Kinase B (PKB/Akt). Most MG sera and some monoclonal anti-AChR antibodies induced a significant increase in IL-6 production by human muscle cells. Furthermore, Akt phosphorylation in response to insulin was decreased in the presence of monoclonal anti-AChR antibodies. Anti-AChR antibodies alter IL-6 production by muscle cells, suggesting a putative novel functional mechanism of action for the anti-AChR antibodies. IL-6 is a myokine with known effects on signaling pathways such as Akt/mTOR (mammalian Target of Rapamycin). Since Akt plays a key role in multiple cellular processes, the reduced phosphorylation of Akt by the anti-AChR antibodies may have a significant impact on the muscle fatigability observed in MG patients.

15 January 2013 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
VMVincent de Montpreville
Vincent de Montpreville
MGMaria-Rosa Ghigna
Maria-Rosa Ghigna
LLLudovic Lacroix
Ludovic Lacroix
BBBenjamin Besse
Benjamin Besse
PBPhilippe Broet
Philippe Broet
PDPeter Dorfmuller
Peter Dorfmuller

6 April 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
MSMuriel Sudres
Muriel Sudres
MMMarie Maurer
Marie Maurer
MRMarieke Robinet
Marieke Robinet
JBJacky Bismuth
Jacky Bismuth
FTFrédérique Truffault
Frédérique Truffault
SBSonia Berrih-Aknin
Sonia Berrih-Aknin
Myasthenia gravis (MG) with anti–acetylcholine receptor (AChR) Abs is an autoimmune disease characterized by severe defects in immune regulation and thymic inflammation. Because mesenchymal stem cells (MSCs) display immunomodulatory features, we investigated whether and how in vitro–preconditioned human MSCs (cMSCs) could treat MG disease. We developed a new humanized preclinical model by subcutaneously grafting thymic MG fragments into immunodeficient NSG mice (NSG-MG model). Ninety percent of the animals displayed human anti-AChR Abs in the serum, and 50% of the animals displayed MG-like symptoms that correlated with the loss of AChR at the muscle endplates. Interestingly, each mouse experiment recapitulated the MG features of each patient. We next demonstrated that cMSCs markedly improved MG, reducing the level of anti-AChR Abs in the serum and restoring AChR expression at the muscle endplate. Resting MSCs had a smaller effect. Finally, we showed that the underlying mechanisms involved (a) the inhibition of cell proliferation, (b) the inhibition of B cell–related and costimulatory molecules, and (c) the activation of the complement regulator DAF/CD55. In conclusion, this study shows that a preconditioning step promotes the therapeutic effects of MSCs via combined mechanisms, making cMSCs a promising strategy for treating MG and potentially other autoimmune diseases.

1 September 2016 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
NLNathaniel B. Langer
Nathaniel B. Langer
OMOlaf Mercier
Olaf Mercier
DFDominique Fabre
Dominique Fabre
JLJames Lawton
James Lawton
SMSacha Mussot
Sacha Mussot
EFElie Fadel
Elie Fadel